Mesoblast (ASX:MSB) logged $0.0444 in loss per share for fiscal 2026, compared with a loss of $0.0846 a year ago, a Thursday filing showed.
For the 12 months ended June 30, revenue was $120.3 million versus $17.2 million previously, the Australia-listed biotechnology company added.
Shares rose past 2% in morning trade Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.